|Bid||57.10 x 100|
|Ask||58.50 x 200|
|Day's Range||57.43 - 58.17|
|52 Week Range||46.01 - 60.45|
|PE Ratio (TTM)||20.10|
|Dividend & Yield||1.56 (2.71%)|
|1y Target Est||N/A|
Incyte (INCY) distributes its key drug, Jakafi, through its own network of specialty pharmacy providers and wholesalers in US markets.
Mixed results for a study with Opdivo in treating first-line kidney cancer give reasons for concern. But how worried should investors really be?
Bristol-Myers Squibb Co NYSE:BMY